Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy

Langenbeck's Archives of Surgery

Volumn 395, Issue 3, 2010, Pages 217-225

  Yeh, Chun Nan ^a   Jung, Shih Ming ^a   Chen, Tsung Wen ^a   Hwang, Tsann Long ^a   Jan, Yi Yin ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Adjuvant chemotherapy; Gastrectomy; Gastric cancer; Thymidylate synthase

Indexed keywords

FLUOROURACIL; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTRECTOMY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; STOMACH CANCER; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; AGED; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STOMACH TUMOR;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; FLUOROURACIL; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 77954686414     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-009-0573-x     Document Type: Article

References (42)

1. Department of Health, Executive Yuan, Taiwan (2007) Annual report of cancer registration
2. Yokota T, Kunii Y, Teshima S, Yamada Y, Saito T, Takahashi M, Kikuchi S, Yamauchi H (1999) Clinicopathologic prognostic features in patients with gastric cancer associated with esophageal or duodenal invasion. Ups J Med Sci 104(3):217-229
3. Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441-1447
4. Hermans J, Bonenkamp JJ (1994) In reply. J Clin Oncol 12:879-880
5. Nakajima T, Ohta K, Ohyama S, Hamajima N (1999) Metaanalysis of adjuvant chemo-therapy trials for gastric cancer at the Cancer Institute Hospital, Tokyo. In: Nakajima T, Yamaguchi T (eds) Multimodality therapy for gastric cancer. Springer-Verlag, Tokyo, pp 27-31
6. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 35:1059-1064
7. Mari E, Floriani I, Tinassi A et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a metaanalysis of published randomized trials. Ann Oncol 11:837-843
8. Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88:21-27
9. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesopha-geal junction. N Engl J Med 345:725-730
10. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
11. Macdonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction: update of the results of Intergroup Study INT-0116 (SWOG9008). Presented at the 2004 Gastrointestinal Cancers Symposium, San Francisco, January 22-24, 2004. Abstract.
12. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T (2002) Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 9:278-286
13. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
14. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3):49-58
15. Ng K, Meyerhardt JA, Fuchs CS (2007) Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J 13:168-174
16. Diasio RB, Johnson MR (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61:199-203
17. IchikawaW(2006) Prediction of clinical outcome of fluoropyrimidinebased chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 9:145-155
18. Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'- deoxyuridine. World J Gastroenterol 10:172-176
19. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G (2002) Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22:2805-2809
20. Lenz HJ, Leichman CG, Danenberg KD et al (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182
21. Johnston PG, Lenz HJ, Leichman CG et al (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412
22. Horishoki T, Danenberg KD, Stadbauer THW et al (1992) Quantitation of thymidylate synthase, dihydroreductase and DTdiaphorose gene expression in human tumors using the polymerase chain reaction. Cancer Res 52:108-116
23. Leichman L, Lenz HJ, Leichman CG, Goshen S et al (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31A:1306-1310
24. Boku N, Chin K, Hosokawa K et al (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 4:1469-1474
25. Yeh KH, Shun CT, Chen CL et al (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82:1626-1631
26. Kawakami K, Graziano F, Watanabe G et al (2005) Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11(10):3778-3783
27. Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y (1998) Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 83:1300-1306
28. Suda Y, Kuwashima Y, Tanaka Y, Uchida K, Akazawa S (1999) Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res 19:805-810
29. Kim JP, Kwon OJ, Oh ST, Yang HK (1992) Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 216:269-279
30. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122-1126 (Pubitemid 24142032)
31. Kelsen DP (1996) Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 23:379-389
32. Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23:397-406
33. Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS (1998) OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized phase III trial. Cancer 83:2054-2059
34. Choi JH, Lim HY, Nam DK et al (2001) Expression of thymidylate synthase in gastric cancer patients treated with 5- fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 84(2):186-192
35. Shiu MH, Perrotti M, Brennan MF (1989) Adenocarcinoma of the stomach: a multivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterology 36:7-12
36. Carneiro F, Seixas M, Sobrinho-Simoes M (1995) New elements for an updated classification of the carcinomas of the stomach. Path Res Pract 191:571-584
37. Macdonald JS, Fleming TR, Peterson RF et al (1995) Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 2:488-494
38. Yu CCW, Levison DA, Dunn JA et al (1995) British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer 71:1106-1110
39. Setälä LP, Kosma V-M, Marin S et al (1996) Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 74:766-772
40. Stelzner S, Emmrich P (1997) The mixed type in Lauren's classification of gastric carcinoma: histologic description and biologic behavior. Gen Diagn Pathol 143:39-48
41. Johnston PG, Fisher ER, Rockette HE et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647
42. Pestalozzi BC, Peterson HF, Gelber RD et al (1997) Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15:1923-1931